Your browser doesn't support javascript.
loading
Pushing the limit of liver regeneration - Safety and survival after monosegment-ALPPS: systematic review and individual patient data meta-analysis.
Murtha-Lemekhova, Anastasia; Fuchs, Juri; Schulz, Erik; Sterkenburg, Anthe; Probst, Pascal; Hoffmann, Katrin.
Afiliação
  • Murtha-Lemekhova A; Department of General, Visceral, and Transplantation Surgery, Ruprecht Karl University, Heidelberg, Germany.
  • Fuchs J; Department of General, Visceral, and Transplantation Surgery, Ruprecht Karl University, Heidelberg, Germany.
  • Schulz E; Department of General, Visceral, and Transplantation Surgery, Ruprecht Karl University, Heidelberg, Germany.
  • Sterkenburg A; Department of General, Visceral, and Transplantation Surgery, Ruprecht Karl University, Heidelberg, Germany.
  • Probst P; Department of General, Visceral, and Transplantation Surgery, Ruprecht Karl University, Heidelberg, Germany; Study Center of the German Surgical Society (SDGC), Heidelberg University Hospital, Heidelberg, Germany.
  • Hoffmann K; Department of General, Visceral, and Transplantation Surgery, Ruprecht Karl University, Heidelberg, Germany. Electronic address: katrin.hoffmann@med.uni-heidelberg.de.
HPB (Oxford) ; 24(3): 353-358, 2022 03.
Article em En | MEDLINE | ID: mdl-34330644
BACKGROUND: Associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) has expanded and spearheaded development in hepatobiliary surgery. Monosegment-ALPPS tests liver regeneration limits and may present as the last feasible curative treatment option. METHODS: Electronic databases (MEDLINE, Web of Science, Google Scholar, Cochrane Library and WHO International Clinical Trials Registry Platform) were searched for publications on mono-ALPPS using a predefined strategy without date or language restrictions. Individual patient data was extracted and analyzed. RESULTS: 237 publications were identified. 19 patients were identified to have undergone mono-ALPPS. Primarily, mono-ALPPS has been utilized as curative treatment for CRLM (17 of 19 cases). Successful mono-ALPPS was possible in FLR above 8% SLV. All patients received either chemotherapy alone or in combination with radiotherapy prior to surgery. 8 of 19 patients experienced PHLF grade A or B. There was no in-hospital mortality described. Recurrent disease has occurred in 7 of 19 patients and 3 have died during follow-up. CONCLUSION: Mono-ALPPS is an experimental procedure that provides a reasonably safe opportunity to curatively treat extensive liver malignancies in patients with FLR as low as 8% SLV. PHLF is the most prevalent complication in mono-ALPPS. Mono-ALPPS should be evaluated in a multicentral study setting.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Hepáticas / Regeneração Hepática Tipo de estudo: Systematic_reviews Limite: Humans Idioma: En Revista: HPB (Oxford) Assunto da revista: GASTROENTEROLOGIA Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Alemanha

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Hepáticas / Regeneração Hepática Tipo de estudo: Systematic_reviews Limite: Humans Idioma: En Revista: HPB (Oxford) Assunto da revista: GASTROENTEROLOGIA Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Alemanha